For Healthcare Professionals

Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19 and Other Community-Acquired Pneumonia.


About the study

Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Informed consent signed
  2. Male and female ≥18 years old;

Patients hospitalized for clinically suspected CAP, defined as the occurrence of (within 48h from hospital admission):

  1. at least 1 of the following signs/symptoms: dyspnea, cough, purulent sputum, crackles (rales) and/or rhonchi
  2. body temperature > 38°C or <36°C (before or during admission) or leucocytosis (> local ULN)
  3. new/increased pulmonary infiltrate(s) by chest imaging
  4. Need for non-invasive supplemental oxygen (NIAID-OS 5-6; Appendix 14.4.1);
  5. SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300;

Females of child-bearing potential and with an active sexual life must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:

  1. Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last IMP dose
  2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last IMP dose
  3. A male sexual partner who agrees to use a male condom with spermicide
  4. A sterile sexual partner

Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, with child-bearing potential, pregnancy test result must be negative before first drug intake.


Exclusion Criteria:

  1. Treatment with IMV or ECMO (NIAID-OS 7);
  2. Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score B or C);
  3. Renal dysfunction: estimated glomerular filtration rate (eGFR, MDRD) <50 mL/min/1.73 m2, or need for haemodialysis or hemofiltration;
  4. Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anaemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
  5. Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period (see section 5.5.2);
  6. Anticipated discharge from the hospital or transfer to another hospital within 72 hours of screening

History of:

  1. intolerance or hypersensitivity to ibuprofen to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib (hypersensitivity to sulphanilamide antibiotics alone, e.g. sulfamethoxazole does not qualify for exclusion)
  2. lactase deficiency, galactosemia or glucose-galactose malabsorption
  3. gastrointestinal bleeding or perforation due to previous NSAIDs therapy or recurrent peptic ulcer/haemorrhage
  4. allergy to reparixin or any component of the IMP formulation
  5. Active bleeding or bleeding diathesis (excluding menses), prior intracranial haemorrhage
  6. Participation in other interventional clinical trials
  7. Clinical condition not compatible with oral administration of the study drug


  1. positive or missing pregnancy test before first drug intake or day 1;
  2. pregnant or lactating women;
  3. women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
  4. Current hospital stay >72h
  5. Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Infectious Pneumonia,Severe COVID-19

Age (in years)



Phase 3

Participants needed


Est. Completion Date

Oct 31, 2024

Treatment type



Dompé Farmaceutici S.p.A identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.